In the current study, we demonstrated that a new LPX formulation loading more siRNA than previously possible, combined with a well-defined acoustic regime with a single element transducer, could functionally deliver EGFR siRNA to tumor cells, resulting in a decrease in tumor burden and a reduction in EGFR expression compared to negative controls. The gene discussed is EGFR; the disease is neoplasm.